A small pilot study found that letermovir, an antiviral drug, was highly effective at preventing cytomegalovirus (CMV) infection in lung transplant recipients with idiopathic pulmonary fibrosis (IPF) — including those with short telomeres, who face extra risks. Only 1 in 24 patients developed detectable CMV while on the drug, and no one stopped treatment due to side effects. The findings support letermovir as a promising prophylaxis option for this vulnerable group.
Lung transplant recipients with idiopathic pulmonary fibrosis (IPF) face a tough road — and CMV infection can make it even harder. A new pilot study offers some encouraging news: letermovir, an antiviral already used in other transplant settings, appears to be both effective and well-tolerated for preventing CMV in this high-risk population, including those with short telomeres (STL), a genetic trait that complicates post-transplant recovery.
In the study of 24 bilateral lung transplant recipients, just 1 patient (4%) had detectable CMV in the blood while on letermovir prophylaxis. No one developed CMV disease, drug resistance, or had to stop treatment due to side effects. However, after letermovir was discontinued, CMV was detected in 36% of participants — particularly among donor-positive/recipient-negative patients, suggesting ongoing vigilance is needed post-prophylaxis.
By the Numbers:
Why it matters: IPF patients with short telomeres are especially vulnerable after lung transplantation, and standard CMV prevention drugs can cause neutropenia — a dangerous side effect. Letermovir's clean safety profile in this group could make it a strong prophylaxis option, though larger studies are needed to confirm these findings.
